



PTO/SB/08A (04-07)

Approved for use through 09/30/2007. OMB 0654-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the American Inventor Protection Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 1 | of | 12

Complete if Known

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al.
Art Unit	1635
Examiner Name	Kimberly Young
Attorney Docket Number	14677-003US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.*	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² If known			
A1					
A2					
A3					
A4					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.*	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ *Number-Kind Code ⁴ If known				
B1		WO 00/44895	08/03/2000	KREUTZER, et al.	Abstract only	
B2		EP 1 144 622 B1	01/20/2000	EUROPHARMA AG		
B3		WO 99/53050	10/21/1999	WATERHOUSE et al.		
B4		WO 99/49029	09/30/1999	GRAHAM		
B5		WO 00/63364	10/26/2000	PACHUK, et al.		
B6		WO 99/32619	07/01/1999	FIRE et al.		
B7		WO 00/44914	08/03/2000	LI, et al.		
B8		WO 99/61631	12/02/1999	HEIFETZ, et al.		
B9		WO 00/01846	01/13/2000	PLEATNICK et al.		
B10		WO 92/19732	11/12/1992	GENSET	Abstract only	
B11		WO 98/05770	02/12/1998	ROTHBARTH, et al.	Abstract only	
B12		WO 98/53083	11/26/1998	GRIERSON, et al.		
B13		WO 99/15682	04/01/1999	BAULCOME, et al.		
B14		DE 196 18 797	11/13/1997	GABNER, et al.		
B15		WO 00/44495	08/03/2000	LLOYD, et al.		
B16		WO 01/36646	05/25/2001	ZERNICKA-GOETZ, et al.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.13 and 1.14. The submission of this form is voluntary. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete If Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 12

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al.
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14667-003US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	ANDREW J. HAMILTON and DAVID C. BALCOMBE, Species of Small Antisense RNA In Posttranscriptional Gene Silencing in Plants, SCIENCE, vol. 286, October 29, 1999, pp. 950-951.	<input type="checkbox"/>
	2	ANDREW FIRE, et al., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature O Macmillan Publishers Ltd. 1993, vol. 391/191, pp. 806-811.	<input type="checkbox"/>
	3	PETER M. WATERHOUSE, et al., Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA, Communicated by W. James Peacock, Commonwealth Scientific and Industrial Research Organization, Canberra, Australia, August 17, 1998, vol. 95, pp. 13959-13964.	<input type="checkbox"/>
	4	MOHAMMAD B. BAHRAMIAN, et al., Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ collagen by a Homologous Transcriptionally Self-Silenced Transgene, Molecular and Cellular Biology, Jan. 1999, vol. 19, No. 1, pp. 274-283.	<input type="checkbox"/>
	5	PHILLIP A. SHARP, RNAi and Double-strand RNA, Genes & Development, vol. 13, pp. 139-141, Cold Spring Harbor Laboratory Press, 1999.	<input type="checkbox"/>
	6	THOMAS TUSCH, et al., Targeted mRNA Degradation by double-stranded RNA in vitro, Genes & Development, vol. 13, pp. 3191-3197; Cold Spring Harbor Laboratory, 1999.	<input type="checkbox"/>
	7	News of the Week, Science, Candidate Gene Silencers Found, Fetal Cells Help Parkinson's Patients, Science, vol. 286, pp. 886, October 29, 1999.	<input type="checkbox"/>
	8	RUEYLING LIN and LEON AVERY, Policing Rogue Genes, Nature, vol. 402, pp. 128-129, November 11, 1999	<input type="checkbox"/>
	9	MICHAEL T. McMANUS, et al., Gene Silencing in Mammals by Small Interfering RNAs, Center for Cancer Research Massachusetts, vol. 3, pp. 737-750, October 2002	<input type="checkbox"/>
	10	MARY K. MONTGOMERY, et al., Double-stranded RNA As a Mediator in Sequence-Specific Genetic Silencing and Co-Suppression, TIG, vol. 14 No. 7, pp. 255-256 and 258, July 1998.	<input type="checkbox"/>

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIÈSE, et al.,
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14667-003US

Sheet

3

of

12

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	JOHN WILEY & SONS, Current Protocols in Molecular Biology, vol. 1, 1999	<input type="checkbox"/>
	12	MICHAEL Y. X. MA, et al., Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach, Biochemistry, vol. 32, No. 7, 1993, pp. 1751-1758.	<input type="checkbox"/>
	13	R. SCHLINSSENLEPPEN, et al., Antisense: From Technology to Therapy, EX LIBRIS [ROCHE], vol. 6, pp.30-55	<input type="checkbox"/>
	14	IIMO HA, et al., A Bulged Lin-4/lin-14 RNA Duplex is Sufficient for <i>Caenorhabditis Elegans</i> Lin-14 Temporal Gradient Formation, Genes & Development vol. 10, pp. 3041-3050	<input type="checkbox"/>
	15	GLENN D. HOKE, et al., Effects of Phosphorothioate Capping on Antisense Oligonucleotide Stability, Hybridization and Antiviral Efficacy Versus Herpes Simplex Virus Infection, Nucleic Acids Research, Vol. 19, No. 20, pp. 5743-5748.	<input type="checkbox"/>
	16	RICHARD H. GRIFFEY, et al., 2'-O-Aminophyl Ribonucleotides; A Zwitterionic Modification that Enhances the Exonuclease Resistance and Biological Activity of Antisense Oligonucleotides, J. Med. Chem. 1996, vol. 39, pp. 5100-5109.	<input type="checkbox"/>
	17	THEO T. NIKIFOROV, et al., Oligodeoxyribonucleotides Containing 4-Thiouridine and 6-Thiodeoxyguanosine as Affinity Labels for the Eco RV Restriction Endonuclease and Modification Methylase, Nucleic Acids Research, vol. 20, pp. 1209-1214.	<input type="checkbox"/>
	18	JANE A. GRASBY, et al., Purine Functional Groups In Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA, Biochemistry 1995, vol. 34, pp. 4068-4076.	<input type="checkbox"/>
	19	THOMAS HORN, et al., Chemical Synthesis and Characterization of Branched Oligodeoxyribonucleotides (bDNA) For Use As Signal Amplifiers in Nucleic Acid Quantification Assays, Nucleic Acids Research, 1997, vol. 25, No. 23, pp. 4842-4849.	<input type="checkbox"/>
	20	REIKO IWASE, et al., Gene Regulation by Decoy Approach (I): Synthesis and Properties of Photo-crosslinked Oligonucleotides, Nucleic Acids Symposium Series No. 37, pp. 203-204	<input type="checkbox"/>
	21	EUGENE SKRIPKIN, et al., Psoralen Crosslinking Between Human Immunodeficiency Virus Type 1 RNA and Primer tRNA3Lys, Nucleic Acids Research, 1996, vol. 24, No. 3, pp. 509-514.	<input type="checkbox"/>

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete If Known

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIÈSE, et al.
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14667-003US

Sheet

4

of

12

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	22	SERGEI M. GRYAZNOV, et al., Template Controlled Coupling and Recombination of Oligonucleotide Blocks Containing Thiophosphoryl Groups, Nucleic Acids Research, 1993, vol. 21, No. 6, pp. 1403-1408	<input type="checkbox"/>
	23	RAVINDERJIT S. BRAICH, et al., Regiospecific Solid-Phase Synthesis of Branched Oligonucleotides. Effect of Vicinal 2',5'-(or 2',3')- and 3',5'-Phosphodiester Linkages on the Formation of Hairpin DNA, Bioconjugate Chem., 1997, vol. 8, pp. 370-377.	<input type="checkbox"/>
	24	ALOKES MAJUMDAR, et al., Targeted Gene Knockout Medicated by Triple Helix Forming Oligonucleotides, Nature Genetics, vol., 20, October 1998, pp. 212-214.	<input type="checkbox"/>
	25	DINESH A. BARAWKAR, et al., Synthesis, Biophysical Properties, and Nuclease Resistance Properties of Mixed Backbone Oligodeoxynucleotides Containing Cationic Internucleoside Guanidinium Linkages: Deoxynucleic Guanidine/DNA Chimeras, Proc. Natl. Acad. Sci. USA, vol. 95, pp 11047-11052, September 1998 Chemistry, Biochemistry.	<input type="checkbox"/>
		POUL NIELSEN, et al., A NOVEL CLASS OF CONFORMATIONALLY RESTRICTED OLIGONUCLEOTIDE ANALOGUES: SYNTHESIS OF 2',3'-BRIDGED MONOMERS AND RNA-Selective Hybridisation, Chem. Commun., 1997, pp. 825-826.	<input type="checkbox"/>
	27	Mark D. PEGRAM, et al., PHASE II STUDY OF RECEPTOR-ENHANCED CHEMOSENSITIVITY USING RECOMBINANT HUMANIZED ANTI-p185Her2/NEU Monoclonal Antibody Plus Cisplatin in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment, Journal of Clinical Oncology, Vol. 16, No. 8 (August), 1998: pp. 2659-2671.	<input type="checkbox"/>
	28	SAYDA M. ELBASHIR, et al., FUNCTIONAL ANATOMY OF siRNAs for MEDIATING Efficient RNAi in Drosophila melanogaster embryo Lysate, The EMBO Journal vol. 20, No. 23, pp. 6877-6888, 2001.	<input type="checkbox"/>
	29	FRANK CZAUDERNA, et al., Structural Variations and Stabilising Modifications of Synthetic siRNAs in Mammalian Cells, Nucleic Acids Research, 2003, vol. 31, No. 11, pp2705-2716.	<input type="checkbox"/>
	30	DIANNE S. SCHWARZ, Evidence that siRNAs Function as Guides, Not Primers, in the Drosophila and Human RNAi Pathways, Molecular Cell, vol. 10, pp. 537-548, September, 2002.	<input type="checkbox"/>
	31	JOHN G. DOENCH, et al., siRNAs Can Function as miRNAs, Genes & Development, vol. 17, pp 438-442, 2003.	<input type="checkbox"/>
	32	ROSALIND C. LEE, et al., The C. Elegans Heterochronic Gene Lin-4 Encodes Small RNAs with Antisense Complementarity to Lin-14, Cell, vol. 75, pp. 843-854, December 3, 1993.	<input type="checkbox"/>

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

5

of

12

Complete if Known

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al.,
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14667-003US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	33	ERIC G. MOSS, et al., The Cold Shock Domain Protein Lin-28 Controls Developmental Timing in C. Elegans and is Regulated by the Lin-4 RNA, Cell, vol. 88, pp. 637-646, March 7, 1997.	<input type="checkbox"/>
	34	YANG SHI, et al., A CBP/p300 Homolog Specifies Multiple Differentiation Pathways in Caenorhabditis Elegans, Genes & Development, vol. 12, No. 7, pp. 943-955, April 1, 1998.	<input type="checkbox"/>
	35	JASON R. KENNERDEIL, et al., Use of dsRNA-Mediated Genetic Interference to Demonstrate that Frizzled and Frizzled 2 Act in the Wingless Pathway, Cell, vol. 95, pp. 1017-1026, December 23, 1998	<input type="checkbox"/>
	36	TIMMONS L. FIRE, A., Specific Interference by Ingested dsRNA., Nature, October 29, 1998, pp. 395.	<input type="checkbox"/>
	37	WARGELIUS A., ELLINGSEN S. Fjose A., Double-stranded RNA Induces Specific Developmental Defects in Zebrafish Embryos, Biochem Biophys Res Commun., Sept. 16, 1999, vol. 1, pp. 156-161.	<input type="checkbox"/>
	38	BAYESIAN STATISTICAL METHODS, RNA-Triggered Gene Silencing, TIG, September 199, vol. 15, No. 9, pp. 304-305.	<input type="checkbox"/>
	39	PHILIP D. ZAMORE, et al., RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals, Cell, vol. 101, pp. 25-33, March 31, 2000.	<input type="checkbox"/>
	40	DR. ANGELIKA FALLERT-MULLER, et al., Lexikon der Biochemie, pp. 447-449.	<input type="checkbox"/>
	41	EUGEN UHLMANN, et al., Antisense Oligonucleotides: A New Therapeutic Principle, vol. 90, No. 4, pp 553-584, June 1990.	<input type="checkbox"/>
	42	MARY K. MONTGOMERY, et al., RNA as a Target of Double-Stranded RNA-Mediated Genetic Interference in Caenorhabditis Elegans, Proc. Nat'l Acad. Sci. US1, vol. 95, pp. 15502-15507, December 1998.	<input type="checkbox"/>
	43	FLORENCE WIANNY, et al, Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development, Nature Cell Biology, vol. 2, February 2000, pp. 70-75.	<input type="checkbox"/>

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete If Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet 6 of 12

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al.,
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14667-003US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	44	BORECKY L, et al., Therapeutic Use of Double-Stranded RNAs in man, Tex Rep Biol Med 1981-1982, vol. 41, pp. 575-81	<input type="checkbox"/>
	45	MADHUR KUMAR, et al., Antisense RNA: Function and Fate of Duplex RNA In Cells of Higher Eukaryotes, Microbiology and Molecular Biology Reviews, December 1998, pp. 1415-1434.	<input type="checkbox"/>
	46	R. KREUTZER, et al., Specific Inhibition of Viral Gene Expression by Double-Stranded RNA in vitro, Nature 391, pp. 806, 1998	<input type="checkbox"/>
	47	SUDHIR AGRAWAL, et al., Self-Stabilized Oligonucleotides as Novel Antisense Agents, Nucleic Acids, Res., vol. 21, 1993.	<input type="checkbox"/>
	48	PATRICK J. PADDISON, et al., Short Hairpin RNAs (shRNAs) Induce Sequence-Specific Silencing in Mammalian Cells, Genes & Development vol. 16, pp. 948-958, 2002.	<input type="checkbox"/>
	49	SAYDA M. ELBASHIR, et al., Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs, Methods, vol. 26, 2002, pp. 199-213.	<input type="checkbox"/>
	50	PIERRE G. MILHAUD, et al., Free and Liposome-encapsulated Double-Stranded RNAs as Inducers of Interferon, Interleukin6, and Cellular Toxicity, Journal of Interferon Research vol. 11, pp. 261-265, 1991.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

7

of

12

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al..
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14667-003US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	51	JENNIFER COUZIN, Breakthrough, Small RNAs Make Big Splash, Science, vol. 298, pp. 2296-7, December 2002	
	52	ANTONIO REGALADO, Turning Off Genes Sheds New Light On How They Work, The Wall Street Journal, August 2002.	
	53	WEISS et al., Managing Complexity, Early Days for RNAi", Biocentury, vol. 11, No. 12, pp. 123, March 2003	
	54	RNA-Interference- A New Weapon Against HIV and Beyond", N. Engl. J. Med. vol. 347, No. 17, pp. 1364-7	
	55	BILLY E, et al., Specific Interference with Gene Expression Induced by Long, Double-Stranded RNA in Mouse Embryonal Teratocarcinoma Cell Lines, PNAS, vol. 98, No. 25, Dec. 2001.	
	56	ELBASHIR SM, et al., Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells, Nature, vol. 411, pp. 494-8, May 2001.	
	57	LIPINSKI et al., Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings, Adv. Drug Delivery Reviews vol 23, pp. 3-25, 1997	
	58	BHAN et al., Nucleic Acid Research, vol. 25, 1997, pp. 3310	
	59	LI et al., Dev. Biology, vol. 210, 1999, pp. 238, Abstr. 346	
	60	NGO et al., PNAS, vol. 95, Dec. 1998, p. 14687	
	61	EXTRACT FROM, Rompp Lexikon der Biotechnologie, George Thieme Verlag, Stuttgart	
	62	VOINNET, O., and Baulcombe, DC., Nature (1997) vol. 398, pp. 553	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

8

of

12

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al.,
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14677-003US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	63	MCCAFFREY, AP et al., Nature (2000), vol. 418, pp. 38-39	
	64	BARBER, GN et al., Mol. and Cell. Biol. (1995), vol. 15, No. 6, p. 3138-46	
	65	BYROM, MW., ET AL., TechNotes 10(1), Ambion, http://www.ambion.com	
	66	S. BLAIR HEDGES, Nature Reviews, Genetics (2002), vol. 3, pp. 838-4	
	9		
	67	SLEDZ, CA., et al., Nature Cell Biol., vol. 5, p. 834-9	
	68	HORNUNG et al., Nature Medicine, vol. 11, No. 3, pp. 263-70, March 2005	
	69	JUDGE et al, Nature Biotechnology, vol. 23, No. 4, pp. 457-62, April 2005	
	70	Applicant's Response to the Written Opinion in the Examination proceedings 28.03.2001.	
	71	BRENNICKE et al., FEMS Microbiol. Rev., Vol. 23, p. 297-316 1999	
	72	PERLER, Nucl. Acids Res., vol. 30, No. 1, pp. 383-4 2002.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

9

or

12

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al.,
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14677-003US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	73	ZHAO, et al., Developmental Biol., vol. 229, pp. 215-23, 2001.	
	74	HU-LIESKOVAN, et al, Cancer Res., vol. 65, No. 19, pp. 8984-92, Oct. 1, 2005.	
	75	CAPLEN, et al, PNAS, vol. 98, No. 17, pp. 9742-7, Aug. 14, 2001.	
	76	HUNTER, et al., JBC, vol. 250, No. 2, pp. 409-17, Jan. 25, 1975.	
	77	MANCHE et al., Mol. Cell, Biol., vol. 12, No. 11, p. 5238-48, Nov. 1992.	
	78	ZENG, et al., RNA, vol. 8, pp.855-60, 2002.	
	79	GB9927444, I/Cancer Res. Camp. Technol. Ltd. Inhibiting Gene Expression.	
	80	ZHENG, et al., RNA, vol. 10, pp. 1934-45, 2004.	
	81	MARTINEZ et al., Cell, vol. 110, pp. 563-74. June 9, 2002.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al.,
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14677-003US

Sheet 10

of 12

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	82	CHIEN, et al., Cancer Gene Therapy, 1-8, 2004.	
	83	SOUTSCHEK, et al., Nature, vol. 432, 1-8, 2004.	
	84	KARBERG, Mach doch mal das Gen aus, Die Zeit, No. 41, 05.10.2006	
	85	Comparative Figure: D60 (Agrawal) v. Opposed Patent	
	86	Comparative Figure D10 (Pachuk) v. Opposed Patent	
	87	ELBASHIR, et al., RNA Interference Is Mediated by 21- and 22-Nucleotide RNAs, Genes & Development vol 15, pp. 188-200.	
	88	NAPOLI, et al., Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans, The Plant Cell, vol. 2, pp. 279-289, April 1990.	
	89	OATES, et al., Too Much Interference: Injection of Double-Stranded RNA Has Nonspecific Effects in the Zebrafish Embryo.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al.,
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14677-003US

Sheet 11

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	90	CAPLEN et al; "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems" Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9742-7.	
	91	KRAYNACK et al., "Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity." RNA. 2006 Jan;12(1):163-76.	
	92	CHIU et al. "siRNA function in RNAi: a chemical modification analysis."RNA. 2003 ep;9(9):1034-48.	
	93	GRÜNWELLER et al. "Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA."Nucleic Acids Res. 2003 Jun 15;31(12):3185-93.	
	94	MORRISSEY et al "Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication." Hepatology. 2005 Jun;41(6):1349-56.	
	95	CHOUNG et al "Chemical modification of siRNAs to improve serum stability without loss of efficacy."Biochem Biophys Res Commun. 2006 Apr 14;342(3):919-27.	
	96	CONRAD et al. "Ribonuclease III: new sense from nuisance." Int J Biochem Cell Biol. 2002 Feb;34(2):116-29.	
	97	ZAMORE et al. "RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals."Cell. 2000 Mar 31;101(1):25-33.	
	98	KALOTA et al. "2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (2'F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing."Nucleic Acids Res. 2006 Jan 18;34(2):451-61. Print 2006.	
	99	WILLIAMS, "Dicing with siRNA." Nat Biotechnol. 2005 Feb;23(2):181-2.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-768-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al.
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14677-003US

Sh
et 12

of 12

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	100	Priority Document of 9927444.1, Cancer Res. Camp. Technol. Ltd. Inhibiting Gene Expression, Publ. Nov. 19, 1999, Issued Nov. 22, 2000.	
	101	Priority Document of US 60/130,377, Methods and Compositions for Inhibiting the Function of Polynucleotide, Issued June 6, 2000.	
	102	Priority Document of US 60/117,635, Double-Stranded RNA Blocks Specific Gene Expression in Multicellular Settings in in Vivo and in Vitro, March 14, 2000.	
	103	KREUTZER, et al., Patent Application DE 199 03 713.2, "Medikament zur Hemmung der Expression eines vorgegebenen Gens, Jan. 30, 1999.	
	104	KREUTZER, et al., Patent Application DE 199 56 568.6, "Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen, Aug. 17, 2000.	
	105	International Preliminary Examination Report, (English Translation) DE 0000244 (IPER), July, 7, 2003.	
	106	KREUTZER, et al., Method and Medicament for Inhibiting the Expression of a defined Gene, (PCT/DE00/00244), Aug. 3, 2000.	
	107		
Examiner Signature	/Kimberly Chong/		Date Considered 05/22/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to be had by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.C./